Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant EC Followed by Docetaxel and Trastuzumab for HER2+ Advanced Breast Cancer
NCT00379015Phase 2Completed
- Sponsor
- Translational Research Center for Medical Innovation
- Start
- Jan 2006
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by Translational Research Center for Medical Innovation. Started Jan 2006; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00379015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379015.